Science and Research

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

  • Peters, S.
  • Dafni, U.
  • Boyer, M.
  • De Ruysscher, D.
  • Faivre-Finn, C.
  • Felip, E.
  • Garrido, P.
  • Girard, N.
  • Guckenberger, M.
  • Haanen, J.
  • Le Pechoux, C.
  • Mornex, F.
  • Ozsahin, M.
  • Paz-Ares, L.
  • Planchard, D.
  • Raben, D.
  • Ramalingam, S.
  • Reck, M.
  • Smit, E.
  • Stahel, R.
  • Stenzinger, A.
  • Swanton, C.
  • Vallone, S.
  • Garassino, M. C.

Keywords

  • Antibodies, Monoclonal/*therapeutic use
  • Antineoplastic Agents, Immunological/*therapeutic use
  • Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
  • *Drug Approval
  • Expert Testimony
  • Humans
  • International Agencies
  • Lung Neoplasms/*drug therapy/pathology
  • Neoplasm Staging
  • Treatment Outcome
Publication details
DOI: 10.1093/annonc/mdy553
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Pages: 161-165 
Number: 2
Work Type: Original
Location: ARCN
Disease Area: LC
Partner / Member: Ghd
Access-Number: 30624547
See publication on PubMed

DZL Engagements

chevron-down